Illumina (ILMN) announced a pilot proteomics program to analyze 50,000 UK Biobank samples in collaboration with deCODE Genetics, Standard BioTools (LAB), Tecan (TCHBF), GSK (GSK), Johnson & Johnson (JNJ), and Novartis (NVS). The pilot program is based on Illumina’s upcoming proteomics assay, Illumina Protein Prep, powered by SOMAmer technology, a next-generation sequencing based solution.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina price target lowered to $140 from $145 at Bernstein
- Illumina launches update to its NovaSeq X Series software
- Illumina price target lowered to $180 from $184 at Evercore ISI
- Cathie Wood’s Ark Invest Offloads Tesla (TSLA) Shares Worth $63M
- Palantir (PLTR) Replaces Super Micro Computer in Nasdaq 100 Shakeup